A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REMDESIVIR PLUS TOCILIZUMAB COMPARED WITH REMDESIVIR PLUS PLACEBO IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19 PNEUMONIA

Date Added
June 29th, 2020
PRO Number
Pro00101225
Researcher
Nandita Nadig

List of Studies


Keywords
Coronavirus, Infectious Diseases, Lung, Pulmonary
Summary

The purpose of this study is to compare the effects, good or bad, of study treatment with remdesivir plus tocilizumab compared with remdesivir by itself on subjects with severe COVID19 pneumonia. In this study, the subject will receive standard supportive care treatment for COVID-19 pneumonia as well as remdesivir, and will additionally receive either tocilizumab, or placebo. About 450 people will take part in this study. Depending on the early results of the study, the total number of people who will take part may be increased to up to 800.

Institution
MUSC
Recruitment Contact
Abigail Grady
(843) 792-2072
gradyabi@musc.edu

Stressors of Inter-ICU Transfer: Family Centered Care through Telehealth

Date Added
December 2nd, 2019
PRO Number
Pro00092555
Researcher
Nandita Nadig

List of Studies


Keywords
Anxiety, Depression
Summary

The purpose of this research study is to reduce psychological distress and improve communication and family centeredness of care for families of Ventilator Dependent Respiratory Failure (VDRF) patients that have undergone inter-ICU transfer by providing them with timely and adequate information about their transfer of care. This will be accomplished by the development and refinement of our Stressors of Inter-ICU Transfer Telehealth Tool (SITT). The study aims to assess reactions to mocked up SITT domains and support resources of 15-20 family members that have undergone inter-ICU transfer as well as 10 clinicians involved in transfer. The data will drive the refinement of the tool to best meet the needs of the families and clinicians.

Institution
MUSC
Recruitment Contact
Kyle White
8437922297
whiteky@musc.edu



-- OR --